DE3505572C2 - - Google Patents
Info
- Publication number
- DE3505572C2 DE3505572C2 DE3505572A DE3505572A DE3505572C2 DE 3505572 C2 DE3505572 C2 DE 3505572C2 DE 3505572 A DE3505572 A DE 3505572A DE 3505572 A DE3505572 A DE 3505572A DE 3505572 C2 DE3505572 C2 DE 3505572C2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- glucose
- liver
- nicotinic acid
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 16
- 235000001968 nicotinic acid Nutrition 0.000 claims description 15
- 229960003512 nicotinic acid Drugs 0.000 claims description 15
- 239000011664 nicotinic acid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229940102223 injectable solution Drugs 0.000 claims description 6
- 208000019423 liver disease Diseases 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229960002737 fructose Drugs 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004470 DL Methionine Substances 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000004140 ketosis Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU841091A HU191598B (en) | 1984-03-20 | 1984-03-20 | Method for the preparation of injection solution suitable preferably against cathosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3505572A1 DE3505572A1 (de) | 1985-09-26 |
| DE3505572C2 true DE3505572C2 (OSRAM) | 1989-04-20 |
Family
ID=10952793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19853505572 Granted DE3505572A1 (de) | 1984-03-20 | 1985-02-18 | Injizierbare loesung, besonders zur behandlung von ketose, und verfahren zur herstellung derselben |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS60260510A (OSRAM) |
| BE (1) | BE901959A (OSRAM) |
| DE (1) | DE3505572A1 (OSRAM) |
| FR (1) | FR2561522B1 (OSRAM) |
| GB (1) | GB2157561B (OSRAM) |
| HU (1) | HU191598B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2245491A (en) * | 1990-06-25 | 1992-01-08 | Medvet Science Pty Ltd | Inhibition of metabolic oxalate formation |
| DE9111598U1 (de) * | 1991-09-18 | 1993-01-28 | Helga Kellermann Mineralgetränke, 5063 Overath | Futtermittel |
| GB9216460D0 (en) * | 1992-08-03 | 1992-09-16 | Lilly Industries Ltd | Veterinary method |
| JP2990686B2 (ja) * | 1994-11-17 | 1999-12-13 | 田辺製薬株式会社 | 水溶性ビタミンｂ類配合総合輸液 |
| JP2001114681A (ja) * | 1999-10-18 | 2001-04-24 | Ajinomoto Co Inc | ケトーシス改善剤 |
| RU2238728C1 (ru) * | 2003-05-06 | 2004-10-27 | Открытое акционерное общество "Новосибхимфарм" | Способ получения раствора никотиновой кислоты для инъекций |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD60477A (OSRAM) * | ||||
| GB500770A (en) * | 1937-09-30 | 1939-02-15 | Vitamol Inc | Improvements in or relating to vitamin compositions for use in feeding poultry and livestock, and methods of making the same |
| FR1350101A (fr) * | 1962-12-13 | 1964-01-24 | Produit pour l'alimentation des animaux | |
| BE739613A (OSRAM) * | 1968-10-03 | 1970-03-02 | ||
| GB1289096A (OSRAM) * | 1968-10-03 | 1972-09-13 | ||
| ZA73288B (en) * | 1972-02-25 | 1973-10-31 | Hoffmann La Roche | Mineral salts containing preparation |
| AU7003774A (en) * | 1974-06-13 | 1975-12-18 | Otsuka Pharma Co Ltd | Parenteral feeding method |
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
-
1984
- 1984-03-20 HU HU841091A patent/HU191598B/hu not_active IP Right Cessation
-
1985
- 1985-02-18 DE DE19853505572 patent/DE3505572A1/de active Granted
- 1985-03-18 BE BE1/11215A patent/BE901959A/fr not_active IP Right Cessation
- 1985-03-19 FR FR8504016A patent/FR2561522B1/fr not_active Expired
- 1985-03-20 GB GB08507176A patent/GB2157561B/en not_active Expired
- 1985-03-20 JP JP60054707A patent/JPS60260510A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HU191598B (en) | 1987-03-30 |
| FR2561522B1 (fr) | 1988-10-14 |
| GB8507176D0 (en) | 1985-04-24 |
| GB2157561B (en) | 1988-01-20 |
| HUT37035A (en) | 1985-11-28 |
| DE3505572A1 (de) | 1985-09-26 |
| GB2157561A (en) | 1985-10-30 |
| BE901959A (fr) | 1985-09-18 |
| FR2561522A1 (fr) | 1985-09-27 |
| JPS60260510A (ja) | 1985-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69328497T2 (de) | Verfahren zur steigerung der wirksamkeit der futterverwertung bei tieren | |
| DE69109376T2 (de) | Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines. | |
| DE69325998T2 (de) | Verwendung von beta-hydroxy-beta-methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen | |
| DE69233115T2 (de) | Weitere therapeutische Verwendungen von L-Methionine und Zusammensetzungen | |
| CH653891A5 (de) | Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier. | |
| DE1792410B2 (de) | Arzneimittelzubereitung zur intravenösen Injektion | |
| DE4037708A1 (de) | Appetitzuegler und verfahren zu seiner anwendung | |
| DE2849226A1 (de) | Verfahren zur wachstumsfoerderung von gefluegel, mittel zu seiner durchfuehrung und deren herstellung | |
| DE2903579A1 (de) | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel | |
| DE3137125C2 (OSRAM) | ||
| DE69733089T2 (de) | Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin | |
| DE2036114B2 (de) | Wäßriges Tetramisolpräparat | |
| DE69003906T2 (de) | Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen. | |
| EP0188810A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Verhinderung oder Behandlung posttraumatischer Nervenschäden nach unfallbedingten Rückenmarks- und/oder Gehirntraumen | |
| DE3013000C2 (de) | Pansendurchtretendes Futterzusatzmittel für Wiederkäuer und dessen Verwendung zur Fütterung von Wiederkäuern | |
| DE2347225C3 (de) | Verwendung von Spurenelementen bei der Injektionstherapie | |
| DE3505572C2 (OSRAM) | ||
| EP0460622B1 (de) | Arzneimittelzubereitung zur systemischen Behandlung von Zier- und Nutzfischen | |
| DE69317716T2 (de) | Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes | |
| DE2335215A1 (de) | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung | |
| EP0349797B1 (de) | Stabilisierte, N-acetylcysteinhaltige Arzneimittelzubereitung | |
| DE60124516T2 (de) | Kombination des lezithins mit ascorbinsäure | |
| DE3153623C2 (OSRAM) | ||
| EP0061508A1 (de) | Verfahren zur Gewinnung von Bienenkittharz enthaltenden Produkten und Bienenkittharz enthaltende Produkte | |
| EP0018550B1 (de) | Mittel zur Behandlung von Muskelerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8101 | Request for examination as to novelty | ||
| 8105 | Search report available | ||
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |